Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study

被引：0
|
作者：
Yuru Fan
Xuan Zhang
Qin Zhang
Liang Zheng
Renpeng Zhou
Cheng Sun
Xihan Wang
Ke Song
Zhusheng He
Honghui Wang
Qian Zhang
Wei Hu
机构：
[1] The Second Affiliated Hospital of Anhui Medical University,Department of Clinical Pharmacology
[2] Jiangsu Hengrui Pharmaceuticals Co.,undefined
[3] Ltd,undefined
来源：
Clinical Pharmacokinetics | 2024年 / 63卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：293 / 302
页数：9
相关论文
共 50 条
  • [1] Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study
    Fan, Yuru
    Zhang, Xuan
    Zhang, Qin
    Zheng, Liang
    Zhou, Renpeng
    Sun, Cheng
    Wang, Xihan
    Song, Ke
    He, Zhusheng
    Wang, Honghui
    Zhang, Qian
    Hu, Wei
    CLINICAL PHARMACOKINETICS, 2024, 63 (03) : 293 - 302
  • [2] Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study
    Christian Friedrich
    Klaus Francke
    Isabella Gashaw
    Christian Scheerans
    Stefan Klein
    Lueder Fels
    Jaclyn A. Smith
    Thomas Hummel
    Alyn Morice
    Clinical Pharmacokinetics, 2022, 61 : 1143 - 1156
  • [3] Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study
    Friedrich, Christian
    Francke, Klaus
    Gashaw, Isabella
    Scheerans, Christian
    Klein, Stefan
    Fels, Lueder
    Smith, Jaclyn A.
    Hummel, Thomas
    Morice, Alyn
    CLINICAL PHARMACOKINETICS, 2022, 61 (08) : 1143 - 1156
  • [4] Safety and pharmacokinetics of BAY 1817080, a P2X3 receptor antagonist, in healthy subjects: Results from a double-blind, randomised study
    Friedrich, Christian
    Francke, Klaus
    Gashaw, Isabella
    Scheerans, Christian
    Klein, Stefan
    Fels, Lueder
    Smith, Jaclyn
    Hummel, Thomas
    Morice, Alyn
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 87 (03) : 1614 - 1616
  • [5] Safety, tolerability, and pharmacokinetics of ibrexafungerp in healthy Chinese subjects: a randomized, double-blind, placebo-controlled phase 1 trial
    Liu, Xiaoyan
    Zhang, Rui
    Li, Rong
    Wu, Qiong
    Pan, Chao
    Yu, Xiangqing
    Liu, Yuhui
    Wang, Benjie
    Yu, Shuwen
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2023, 67 (12)
  • [6] SAFETY OF AMISELIMOD IN HEALTHY SUBJECTS: RESULTS FROM A PHASE 1 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Hanauer, Stephen
    O'Reilly, Terry
    Lester, Robert
    Slatkin, Neal
    Lee, Jimin
    Franklin, Howard
    Bulawski, Angela
    Israel, Robert
    GASTROENTEROLOGY, 2021, 160 (03) : S1 - S2
  • [7] SAFETY OF AMISELIMOD IN HEALTHY SUBJECTS: RESULTS FROM A PHASE 1 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Hanauer, Stephen
    O'Reilly, Terry
    Lester, Robert
    Slatkin, Neal
    Lee, Jimin
    Franklin, Howard
    Bulawski, Angela
    Israel, Robert
    INFLAMMATORY BOWEL DISEASES, 2021, 27 : S1 - S1
  • [8] Safety, tolerability, and pharmacokinetics of HRS9432(A) injection in healthy Chinese subjects: a phase-I randomized, double-blind, dose escalation, placebo-controlled study
    Yan, Xin
    Huang, Yuanyuan
    Xie, Jinlian
    Wu, Qian
    Yang, Shuang
    Yang, Xiaoyan
    Chen, Honghui
    Huang, Jie
    Yang, Guoping
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2024, 68 (07) : e0052424
  • [9] P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study
    Abdulqawi, Rayid
    Dockry, Rachel
    Holt, Kimberley
    Layton, Gary
    McCarthy, Bruce G.
    Ford, Anthony P.
    Smith, Jaclyn A.
    LANCET, 2015, 385 (9974): : 1198 - 1205
  • [10] Phase 1, Randomized, Double-Blind, Placebo-Controlled Studies of the Safety, Tolerability and Pharmacokinetics of Naldemedine in Healthy Volunteers
    Fukumura, Kazuya
    Yokota, Takaaki
    Baba, Yuko
    Camilo, Juan
    Ferreira, Arjona
    GASTROENTEROLOGY, 2016, 150 (04) : S537 - S538
12345